Prosecution Insights
Last updated: November 20, 2026
Application No. 18/252,714

ECTOPIC CELLULAR GROWTH FACTOR EXPRESSION FOR LOW-COST PRODUCTION OF CELL-CULTURED FOODS

Final Rejection §102§112
Filed
May 11, 2023
Priority
Nov 12, 2020 — provisional 63/112,682 +2 more
Examiner
STAVROU, CONSTANTINA E
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Trustees of Tufts College
OA Round
2 (Final)
42%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
39 granted / 93 resolved
-18.1% vs TC avg
Strong +36% interview lift
Without
With
+36.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
58 currently pending
Career history
175
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
43.1%
+3.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 93 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-9, 11, 15-18, 21, 26, 43, 46, 54, and 56-57 are currently pending. Claims 1, 4-9, 11 and 56-57 is amended. Claims 21, 26, 43, 46, and 54 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Claims 10, 12-14, 19-20, 22-25, 27-42, 44-45, 47-53, and 55 remain cancelled. Claims 1-9, 11, 15-18, and 56-57 have been considered on the merits. Withdrawn Objections/Rejections The objections made onto the specification are withdrawn in light of the amendments made onto the specification submitted on 08/21/2026. The objection made onto claim 1 is withdrawn in light of the amendments made in the reply submitted on 08/21/2026. The rejections made under 35 U.S.C. 102 and 103 are withdrawn in light of the amendments made in the reply submitted on 08/21/2026. New Rejections Necessitated by Amendment Claim Objections Claim 1 is objected to because of the following informalities: it is recommended to amend the preamble to read “growth factors, growth factor receptors, and/or cytokines” because the claimed options in claim 1 provide a mix of each category. Appropriate correction is recommended. Claim 2 is objected to because of the following informalities: it is recommended to amend “with the ectopically expressed growth factors or cytokines” to read “with the ectopically expressed growth factors, growth factor receptors, and/or cytokines” to match the newly amended preamble of claim 1. Appropriate correction is recommended. Claims 4, 5, 7, 9, 11, 56, and 57 is objected to because of the following informalities: it is recommended to amend the recitations of “growth factors, growth factor receptors, or cytokines” to read “growth factors, growth factor receptors, and/or cytokines” to maintain the language used in the preamble throughout the claims. Appropriate correction is recommended. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9, 11, 15-18, and 56-57 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 contains the phrase “(a) fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), and transferrin, and (2) one or both of insulin-like growth factor (IGF), or IGF-1 LR3;”, which renders the claim indefinite. It is not clear what the number “(2)” is referring to in the claim since there is no limitation described as (1). Further, this renders the claim unclear as to what selection “(a)” comprises. Appropriate correction is required. The dependent claims are included in this rejection due to dependency on claim 1. The preamble of claim 8 has been amended to read “the modified non-human cell of claim 1 ectopically expressing growth factors and/or cytokines” which renders the claim indefinite. The preamble of dependent claim 8 has been amended such that it does not match the preamble of the independent claim 1. The preamble should read “The modified non-human cell of claim 1,”. Appropriate correction is required. Response to Arguments Applicant’s arguments, see Remarks, filed 08/21/2026, with respect to the rejections under 35 U.S.C. 102 and 103 have been fully considered and are persuasive. The rejection of the claims has been withdrawn. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Examiner Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CONSTANTINA E STAVROU whose telephone number is (571)272-9899. The examiner can normally be reached M-F 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CONSTANTINA E. STAVROU Examiner Art Unit 1632 /TITILAYO MOLOYE/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

May 11, 2023
Application Filed
Feb 25, 2026
Non-Final Rejection mailed — §102, §112
Aug 21, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766167
COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS
6y 0m to grant Granted Oct 20, 2026
Patent 12760083
CHIMERIC RECEPTOR THERAPY
4y 9m to grant Granted Oct 13, 2026
Patent 12747423
CELL CULTURE MEDIUM FOR CULTURING EXTRACELLULAR VESICLES AT HIGH CONCENTRATION AND METHOD FOR PREPARING CONDITIONED MEDIUM CONTAINING HIGH CONCENTRATION OF EXTRACELLULAR VESICLES USING CELL CULTURE MEDIUM
5y 8m to grant Granted Sep 29, 2026
Patent 12716058
METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HLA HOMOZYGOUS IMMUNE CELLS
7y 4m to grant Granted Aug 25, 2026
Patent 12678463
ACTIVATED MESENCHYMAL STEM CELLS FOR TREATING LIMB ISCHEMIA
4y 4m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
42%
Grant Probability
78%
With Interview (+36.1%)
3y 11m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 93 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month